Latest uniQure News & Updates

See the latest news and media coverage for uniQure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
uniQure

Gene therapy company targeting neurological and rare diseases

uniqure.com
Headquarters
Amsterdam, Netherlands
Founded year
1998
Company type
Public company
Number of employees
50–350
Industry
Pharmaceuticals

Last updated

Latest news about uniQure

In short: uniQure reached an agreement with the FDA to pursue an accelerated approval pathway for AMT-130, its Huntington's disease gene therapy.

Company announcements

uniQure

uniQure reported Q1 2026 financial results

The company also highlighted recent progress across its business.

Unlock all announcements with a

Media coverage

Investing.com

uniQure's second-quarter loss widened, but FDA approval path is becoming clearer

Chief Financial Officer Christian Klemt said that the company's cash reserves can last until 2030, covering funding for confirmatory trial enrollment, commercial launch preparation, ongoing clinical trials, and possible later-stage development of other pipeline candidates. Management Commentary Chief Executive Officer Matt Kapusta said that the company has achieved a key regulatory milestone: "In June 2026, we held a Type B meeting with the FDA, during which both parties agreed on the reasonableness of submitting the AMT-130 BLA under the accelerated approval pathway based on three-year data." Chief Medical...

Morningstar

uniQure NV (QURE)

See the latest uniQure NV stock price (QURE:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Unlock all articles with a

Never miss news about uniQure

Track uniQure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

uniQure competitors & trending companies

Browse news for competitors to uniQure and other trending companies.